Skip to main content

Drug Interactions between Belviq XR and Yohimar

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

yohimbine lorcaserin

Applies to: Yohimar (yohimbine) and Belviq XR (lorcaserin)

MONITOR: Theoretical concerns exist that coadministration of lorcaserin and drugs used for the treatment of erectile dysfunction may increase the risk of priapism (painful erections greater than 6 hours in duration). Lorcaserin may cause priapism due to 5-HT2C receptor agonism. If not treated promptly, priapism can result in irreversible damage to the erectile tissue.

MANAGEMENT: There is limited experience with the combination of lorcaserin and medications indicated for erectile dysfunction. Caution is advised if coadministration is necessary, particularly in patients with risk factors for priapism such as sickle cell anemia, multiple myeloma, leukemia, or anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, Peyronie's disease). Men who have an erection lasting longer than 4 hours, whether painful or not, should immediately discontinue these drugs and seek emergency medical attention.

References

  1. "Product Information. Belviq (lorcaserin)." Eisai Inc (2012):

Switch to consumer interaction data

Drug and food interactions

Minor

lorcaserin food

Applies to: Belviq XR (lorcaserin)

Food does not appear to significantly affect the absorption and oral bioavailability of lurasidone. In twelve adult volunteers (6 men and 6 women), administration of a single 10 mg oral dose of lorcaserin following a high-fat (approximately 50% of total caloric content of the meal) and high-calorie (approximately 800 to 1000 calories) meal resulted in less than 10% increases in lorcaserin peak plasma concentration (Cmax) and systemic exposure (AUC) compared to administration in the fasted state. The time to reach peak concentration (Tmax) was delayed by approximately 1 hour in the fed state. Lorcaserin may be administered with or without food.

References

  1. "Product Information. Belviq (lorcaserin)." Eisai Inc (2012):

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer